Authors
Latest:
Relaunching ReformThis time, powerful interest groups (like pharma) that sank the Clinton healthcare bill are on the side of change
Latest:
The Changing Pharmaceutical Sales LandscapeSales forces can achieve compliance and excellence through individual behavioral fine-tuning and company-wide cultural adjustment.
Latest:
The Push for Modern ManufacturingAntiquated manufacturing processes cost pharma money-a fact widely known and accepted in the industry. At some facilities, rejected batches, rework, and lengthy investigations have become a way of life, and by some estimates can inflate production costs by as much as 10 percent. According to G.K. Raju, executive director of the Pharmaceutical Manufacturing Initiative at the Massachusetts Institute of Technology, manufacturing consumes an estimated 25 percent of drug company revenues.
Latest:
Open Payments: Key Compliance ConsiderationsOn June 30, the Centers for Medicare and Medicaid Services (CMS) released the first full year of data under The Affordable Care Act’s transparency program, also known as Open Payments or the "Sunshine Act." This included approximately 11.4 million records totaling about $6.5 billion in payments made to 607,000 physicians and 1,121 teaching hospitals by 1,444 reporting entities during 2014. Combined with CMS’s September 2014 release of 2013 data for the period Aug. 1, 2013 through Dec.
Latest:
22nd Annual Industry Audit: The Pharma Value PictureA look at the performance of the top 15 companies across seven business-key metrics, including the latest standouts in market capitalization and creating shareholder value.
Latest:
Connecting with Customers in Digital SpaceDani Friedland examines what Johnson & Johnson and other pharmaceutical companies are doing to succeed online.
Latest:
Update from Washington: FDAMALast November, President Clinton formally signed into law the Food and Drug Administration Modernization Act, sweeping bipartisan congressional legislation focused on reforming the agency's regulation of food, drugs, medical devices and cosmetics. Overall, the new law is considered a triumph by both the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization because it embraces many of the FDA legislative reform recommendations the industries had proposed to streamline the drug regulatory process.
Latest:
The Seven Deadly Sins of Product LaunchesAs more new products vie for payer and prescriber attention, the stakes around launch success are higher than ever. Stan Bernard outlines the key traps to avoid in getting things right - when it really counts.
Latest:
Managing the InnovatorInnovative products, and the research and development teams that produce them, are pharma's life blood. So it's no surprise that, according to PE's 2003 Top 50 Pharma, the largest 20 pharma companies alone spent $45.5 billion on R&D.
Latest:
Only Connect: Finding the Key to Digital MarketingJim Currie and Baber Ghauri talk to Pharm Exec about making connections that resonate with audiences in a digital world.
Latest:
Bottom Line BoosterGiven the colossal revenue generated by just one blockbuster drug, it's no surprise that R&D always finds its way to the top of management's agenda. But now more than ever, pharmaceutical companies can't thrive on discovery alone. Price pressure from the public and private sectors drives companies to create savings through operational efficiencies. One of the biggest areas for financial gain"better management of capital assets"is often overlooked.
Latest:
Optimal Pricing StrategiesPricing has never been more of a key issue for the industry than it is right now. Yet, even with the increased importance of pricing strategies, a lack of focus on critical market factors leads many manufacturers to forego profits or increase their vulnerability to aggressive payers. Aligning pricing and contracting can achieve a sustainable competitive advantage-if product managers objectively assess a product's clinical benefits and address two key questions:
Latest:
Basic Training: Trends in Learning & Development DepartmentsCan pharma take its talent-and its earning potential-to the next level with employee education?
Latest:
Value Extraction: Mining for Gold in Late-Stage ProductsIn the second of three blogs on how digital strategy and a “data culture” can help define and deliver value, David Ormesher focuses on Value Extraction.
Latest:
Report Sees Huge Pharma Tax Hike Over Next DecadeA new study of industry tax professionals conducted by PricewaterhouseCoopers predicts higher taxes for Big Pharma in the wake of the global economic downturn. What can your company do to remain competitive and discover new incentives?
Latest:
Video Games: Key to the Future of Healthcare?Initial survey and results suggest that health games and virtual worlds bear the potential to be "game changers" by improving education, provoking greater engagement, and engendering positive behavior to enhance health and wellness.
Latest:
Taxing Times for French PharmaWhile French politics has taken a decisive shift to the left with the election of the country’s first socialist president for 17 years
Latest:
Under InvestigationI thought I knew all of the definitions for healthcare compliance when I left my job at a traditional pharma company in 1998 to become chief operating officer of a company that sold both medical diagnostics products and pharmaceuticals.
Latest:
Three Challenges to CRO SuccessThe last few years have seen tremendous consolidation in both the pharmaceutical and contract research industries. The impact among pharma companies has created a heightened demand for productivity. Consequently, contract research organizations (CROs) have struggled to find their footing in a business where the number of customers has shrunk and the demand for speed and cost-effectiveness has risen. Delivering service excellence when customers' names and addresses are changing regularly is a challenge, resulting in disrupted continuity, broken lines of communication, and policies and relationships thrown into disarray.
Latest:
The Need for Intelligent IP managementSimon Webster looks at the role of intellectual property (IP) management in protecting pharmaceutical company products.
Latest:
Pairing UpMarket researchers often fail to realize that whenever they collect competitor information they are in fact collecting competitive intelligence. The same is true in reverse.
Latest:
Tools Are Just the BeginningPharma companies are committed to using electronic data capture in clinical trials. Technology adoption will continue to grow, as FDA and consumers want faster safety data.
Latest:
The evolution of the pharmaceutical sales representativeHow the job has changed over the years.
Latest:
ISPOR Task Force Grapples with Value QuestionsISPOR's Value Assessment Stakeholder Conference showed its Special Task Force still reaching for clarification around the subject, writes Ansis Helmanis.
Latest:
Syncing Personalized Medicine and MarketingThe age of genomics is giving rise to highly specialized diagnostic tools, targeted therapies, and personalized drug monitoring. This new generation of individualized treatments will require life sciences companies to evolve how they reach and educate the healthcare community. Are your commercial operations up to the task?
Latest:
Is access possible in tough markets?In the 1990s, the promise of healthcare reform and the rise of managed care created unique markets, where the business of selling pharmaceuticals has been at the mercy of often unknown pressures. These market fluctuations have created physician access trouble for the pharmaceutical industry, and tricks of the trade no longer get reps through the door.
